• SPX
  • $5,714.58
  • 0.26 %
  • $14.64
  • DJI
  • $42,078.90
  • 0.16 %
  • $67.30
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,290.29
  • 0.09 %
  • $7.77
  • IXIC
  • $17,979.46
  • 0.34 %
  • $60.99
TCR2 Therapeutics Inc. (TCRR) Stock Price, News & Analysis

TCR2 Therapeutics Inc. (TCRR) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$1.48
Day's range
$1.48
50-day range
$1.3401
Day's range
$2.04
  • Country: US
  • ISIN: US87808K1060
52 wk range
$0.82
Day's range
$3.88
  • CEO: Dr. Garry E. Menzel M.B.A., Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -7.19
  • Piotroski Score 2.00
  • Grade Neutral
  • Symbol (TCRR)
  • Company TCR2 Therapeutics Inc.
  • Price $1.48
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $1.48
  • Day High $1.48
  • Year High $3.88

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/07/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $5.00
  • High Stock Price Target $5.00
  • Low Stock Price Target $5.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.20
  • Trailing P/E Ratio -0.35238095238095
  • Forward P/E Ratio -0.35238095238095
  • P/E Growth -0.35238095238095
  • Net Income $-151,822,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.